Fragoulakis Vasilios, Mitropoulou Christina, Katelidou Daphne, van Schaik Ron H, Maniadakis Nikolaos, Patrinos George P
1 Department of Pharmacy, University of Patras School of Health Sciences , Patras, Greece .
2 Department of Health Services Management, National School of Public Health , Athens, Greece .
OMICS. 2017 Feb;21(2):67-73. doi: 10.1089/omi.2016.0161. Epub 2017 Jan 24.
In modern healthcare systems, the available resources may influence the morbidity, mortality, and-consequently-the level of healthcare provided in every country. This is of particular interest in developing countries where the resources are limited and must be spent wisely to address social justice and the right for equal access in healthcare services by all the citizens in economically viable terms. In this light, the current allocation is, in practice, inefficient and rests mostly on each country's individual political and historical context and, thus, does not always incorporate decision-making enabled by economic models. In this study, we present a new economic model, specifically for resource allocation for genomic medicine, based on performance ratio, with potential applications in diverse healthcare sectors, which are particularly appealing for developing countries and low-resource environments. The model proposes a new method for resource allocation taking into account (1) the size of innovation of a new technology, (2) the relative effectiveness in comparison with social preferences, and (3) the cost of the technology, which permits the measurement of effectiveness to be determined differently in the context of a specific disease and then to be expressed in a relative form using a common performance ratio. The present work expands on previous work for innovation in economic models pertaining to genomic medicine and supports translational science.
在现代医疗体系中，可用资源可能会影响每个国家的发病率、死亡率，进而影响所提供的医疗水平。这在资源有限的发展中国家尤为重要，这些国家必须明智地使用资源，以便在经济可行的条件下实现社会公平以及全体公民平等获得医疗服务的权利。有鉴于此，目前的资源分配实际上效率低下，主要取决于每个国家各自的政治和历史背景，因此并不总是纳入基于经济模型的决策。在本研究中，我们提出了一种新的经济模型，特别是基于绩效比的基因组医学资源分配模型，该模型在不同医疗领域具有潜在应用，对发展中国家和资源匮乏地区尤其具有吸引力。该模型提出了一种新的资源分配方法，该方法考虑到：（1）新技术的创新规模；（2）与社会偏好相比的相对有效性；（3）技术成本，这使得能够在特定疾病的背景下以不同方式确定有效性的衡量标准，然后使用共同的绩效比以相对形式表示。本研究拓展了以往关于基因组医学经济模型创新的工作，并支持转化科学。
